Detalhe da pesquisa
1.
Efficacy and safety of netupitant/palonosetron combination (NEPA) in preventing nausea and vomiting in non-Hodgkin's lymphoma patients undergoing to chemomobilization before autologous stem cell transplantation.
Support Care Cancer
; 30(2): 1521-1527, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34533630
2.
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Ann Hematol
; 100(2): 429-436, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33161453
3.
High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab.
Acta Haematol
; 126(1): 44-51, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21430371
4.
Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantation: a phase IIa, multicenter study.
Bone Marrow Transplant
; 55(11): 2114-2120, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32346078
5.
Outcome of Very Late Relapse in Patients with Hodgkin's Lymphomas.
Adv Hematol
; 2011: 707542, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21253449